Industry Groups Want Quick Death for Nevada Rx Pricing Law

A new Nevada law will imperil future biomedical innovation and put drugmakers’ trade secrets and patents at risk, pharmaceutical industry groups claim (Pharmaceutical Research and Manufacturers of America v. Sandoval, D. Nev., 2:17-cv-02315, complaint filed 9/1/17).

In a lawsuit filed in the U.S. District Court for the District of Nevada Sept. 1, the Pharmaceutical Research and Manufacturers of America (PhRMA) and the Biotechnology Innovation Organization (BIO) said the Nevada law, SB 539—which requires drugmakers and pharmacy benefit managers (PBMs) to disclose pricing and rebate information for diabetes drugs—is unconstitutional. The law became effective this summer but hasn’t ...